fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Breakthrough dual therapy emerges for common form of liver cancer

Written by | 25 Jun 2020

Article written by Bruce Sylvester Investigators have validated a first-line combination therapy that significantly improves survival in patients with hepatocellular carcinoma, the most common liver cancer.

Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in phase III ETHOS trial.- AstraZeneca

Written by | 25 Jun 2020

Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or… read more.

FDA approves Keytruda to treat cutaneous squamous cell carcinoma that is not curable by surgery or radiation.- Merck Inc.

Written by | 25 Jun 2020

Merck announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that… read more.

FDA grants emergency use authorisation for GenePro SARS-CoV-2 Test as diagnostic for COVID-19.- Gencurix

Written by | 25 Jun 2020

Gencurix has received FDA Emergency Use Authorization for its GenePro SARS-CoV-2 Test. It is the second RT-PCR test that Gencurix has launched following the first test assay, GenePro… read more.

Fulcrum THerapeutics initiates phase III trial of losmapimod to treat COVID-19.

Written by | 25 Jun 2020

Fulcrum Therapeutics, Inc. announced that it received early notification from the FDA that the company may proceed with initiating a Phase III, randomized, double-blind, placebo-controlled trial of losmapimod… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.